Gary Stobbe, MD
Neurology · Seattle, WANPI 1528054616
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Roche Products Limited at 55.5% of the total.
Across 8 payments — averaging $323.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$1K
- Impel Pharmaceuticals Inc.$1K
- Genentech, Inc.$78
- EMD Serono, Inc.$73
Across 88 payments — averaging $2088.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$105K
- Genentech, Inc.$50K
- Hoffmann-la Roche Limited$28K
- GW Research Limited$457
What the payments were for
- Consulting fees$1,00039%
- Travel & lodging$1,20647%
- Food & beverage$30112%
- Education$783%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 2 | $1,434 |
| Impel Pharmaceuticals Inc. | 1 | $1,000 |
| Genentech, Inc. | 2 | $78 |
| EMD Serono, Inc. | 3 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,434
- Trudhesa$1,000
How this compares
$2,585 in reported general payments places this provider in the 75th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 35 | $10,045 |
| Tegretol XrCarbamazepine | 18 | $9,662 |
| Oxcarbazepine | 41 | $7,874 |
| Lamotrigine | 97 | $7,489 |
| Lurasidone Hcl | 27 | $7,407 |
| Carbamazepine ErCarbamazepine | 33 | $6,534 |
| Fluvoxamine Maleate | 102 | $6,468 |
| Risperidone | 176 | $5,950 |
| Divalproex Sodium | 84 | $5,934 |
| Sertraline Hcl | 184 | $4,793 |
| Paliperidone ErPaliperidone | 14 | $4,611 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,395 |
| Fluoxetine Hcl | 85 | $2,754 |
| Aripiprazole | 98 | $2,752 |
| Trazodone Hcl | 94 | $2,381 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.